Polity3 October 20264 min read
Supreme Court asks Centre why one retailer margin should not cover all essential medicines
The Supreme Court of India has criticised the wide gap between the wholesale price and the Maximum Retail Price (MRP) of essential life-saving medicines. Describing a 10-fold markup on a cancer drug as "broad daylight dacoity", the Court asked the Union Government why a uniform retailer margin should not be applied to all essential medicines and medical devices.
The remark points to a gap in how India controls drug prices. Ceiling prices apply to a defined list of medicines, while launch prices and trade margins on most of the market are left largely free.
How drug prices are controlled
Medicines are declared essential commodities under the Essential Commodities Act, 1955, which lets the government control their production, supply and pricing. The Drugs (Prices Control) Order, 2013 (DPCO), issued under that Act, gives the legal framework. The National Pharmaceutical Pricing Authority (NPPA), an independent body under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, enforces it and recovers overcharges from companies.
Scheduled drugs are those on the National List of Essential Medicines (NLEM). The NLEM 2022 has 388 medicines and about 1,000 formulations. For these, the NPPA sets the ceiling price as the simple average of the Price to Retailer (PTR) of all brands with at least a 1% market share, then adds a fixed 16% notional retailer margin. The ceiling is revised every year in line with the Wholesale Price Index.
For non-scheduled drugs, manufacturers can fix the launch price themselves. They cannot raise the MRP by more than 10% a year.
Why the markups arise
Non-scheduled drugs are said to make up 80% of the market, and their launch prices are uncapped. Companies therefore build in large trade margins, often above 500-1000%, to induce hospitals, distributors and chemists to push their brands. The NLEM covers only about 20% of total market turnover, so most critical and rare-disease drugs fall outside the ceiling-price net.
Patients in corporate hospitals are described as captive buyers, made to buy from in-house pharmacies at the printed MRP. Patients also generally lack the knowledge to question a prescription or ask for a cheaper generic equivalent.
The cost falls on households. National Health Accounts estimates for 2022-23 put out-of-pocket expenditure at 43.4% of total health expenditure. NSSO 75th Round data indicate that medicines account for roughly 70% of out-of-pocket healthcare spending. It is argued that letting manufacturers set initial MRPs regardless of manufacturing cost violates Article 21 of the Constitution.
What has been done and what remains
Using its extraordinary powers, the NPPA has capped trade margins under Trade Margin Rationalisation. This produced sharp price cuts on 42 anti-cancer medicines, coronary stents, orthopaedic knee implants and oxygen concentrators.
Other measures include:
- The Pradhan Mantri Bhartiya Janaushadhi Pariyojana, which supplies generic medicines through Jan Aushadhi Kendras at prices 50% to 80% lower than branded ones.
- Free essential medicines at public facilities, from Primary Health Centres to district hospitals, under the National Health Mission.
- The NPPA's Pharma Sahi Daam app, which lets consumers check prices, find generic substitutes and complain about overcharging.
- A revised Schedule M, which makes Good Manufacturing Practices at World Health Organization standard mandatory for all pharmaceutical MSMEs.
Quality oversight remains divided between the Central Drugs Standard Control Organisation (CDSCO) under the Health Ministry and state drug regulators, which leads to uneven enforcement. The WHO has raised concern over substandard Indian cough syrups contaminated with diethylene glycol and ethylene glycol, linked to around 300 child deaths.
Proposals for closing the gaps include a cap on trade margins across the whole supply chain instead of only on NLEM drugs, strict enforcement of National Medical Commission guidelines requiring doctors to prescribe by generic names, and a unified drug regulatory framework that merges state and central licensing powers.